Free Trial

Axsome Therapeutics (AXSM) Earnings Date, Estimates & Call Transcripts

Axsome Therapeutics logo
$93.17 -4.20 (-4.31%)
(As of 11/15/2024 ET)

Axsome Therapeutics Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 18Estimated
Actual EPS
(Nov. 12)
-$1.34 Beat By $0.04
Consensus EPS
(Nov. 12)
-$1.38

Axsome Therapeutics issued Q3 2024 earnings on November 12, 2024, reporting an EPS of -$1.34, which topped the consensus estimate of -$1.38 by $0.04. Quarterly revenue was reported to be $104.76 million, above analysts' expectations of $98.71 million. With a trailing EPS of -$6.53, Axsome Therapeutics' earnings are expected to grow next year, from ($4.75) to ($1.22) per share.

AXSM Upcoming Earnings

Axsome Therapeutics' next earnings date is estimated for Tuesday, February 18, 2025, based off prior year's reporting schedules.

Get Axsome Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Axsome Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

AXSM Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AXSM Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Axsome Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20244-$1.33-$1.26-$1.30
Q2 20244-$1.42-$1.31-$1.37
Q3 20244-$1.55-$1.39-$1.47
Q4 20244-$1.37-$1.10-$1.23
FY 202416-$5.67-$5.06-$5.37
Q1 20253-$1.52-$1.05-$1.22
Q2 20253-$1.33-$0.62-$0.87
Q3 20253-$0.83$0.14-$0.33
Q4 20253-$0.47$1.06$0.26
FY 202512-$4.15-$0.47-$2.17
Q1 20261-$0.59-$0.59-$0.59
Q2 20261-$0.02-$0.02-$0.02
Q3 20261$0.83$0.83$0.83

Axsome Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/18/2025
(Estimated)
------- 
11/12/2024Q3 2024-$1.38-$1.34+$0.04-$1.34$98.71M$104.76M        
8/5/2024Q2 2024-$1.30-$1.24+$0.06-$0.81$84.53M$87.17M
5/6/2024Q1 2024-$1.20-$1.09+$0.11-$0.74$69.91M$75.00M  
2/20/2024Q4 2023-$1.21-$0.73+$0.48$0.62$70.38M$71.53M    
11/6/2023Q3 2023-$1.24-$1.32 -$0.08-$1.32$54.88M$57.79M      
8/7/2023Q2 2023-$1.24-$1.00+$0.24-$0.46$40.19M$46.70M  
5/8/2023Q1 2023-$1.13-$0.22+$0.91-$0.18$26.87M$94.58M  
2/27/2023Q4 2022-$1.18-$1.28 -$0.10-$1.15$21.51M$24.37M      

Axsome Therapeutics Earnings - Frequently Asked Questions

Axsome Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based off last year's report dates. Learn more on AXSM's earnings history.

In the previous quarter, Axsome Therapeutics (NASDAQ:AXSM) reported ($1.34) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.38) by $0.04. Learn more on analysts' earnings estimate vs. AXSM's actual earnings.

The conference call for Axsome Therapeutics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Axsome Therapeutics's latest earnings report can be read online.
Read Transcript

Axsome Therapeutics (NASDAQ:AXSM) has a recorded annual revenue of $270.60 million.

Axsome Therapeutics (NASDAQ:AXSM) has a recorded net income of -$239.24 million. AXSM has generated -$6.53 earnings per share over the last four quarters.

Axsome Therapeutics's earnings are expected to grow from ($4.75) per share to ($1.22) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:AXSM) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners